Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Gilead Gets CHMP Nod for New HIV Combo

Executive Summary

Gilead has received the green light in the EU for marketing its newest fixed-dose HIV treatment Odefsey but its cannibalization of predecessor product Complera will not reach levels expected in the US as generic versions of older HIV combos are set to arrive earlier in the EU.


Related Content

Gilead HIV Sales Getting Boost From Switches To TAF-Based Combos
2Q Pharma Results Preview: What Lies Ahead
FDA OK's Gilead's 'TAF' Combo HIV Drug Odefsey


Related Companies